Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Zoetis Securities Fraud Class Actions
Business securities fraud lawsuit

Zoetis Securities Fraud Class Actions

Analysis based on 87 articles · First reported May 18, 2026 · Last updated Jun 10, 2026

Sentiment
-70
Attention
4
Articles
87
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The multiple class action lawsuits against Zoetis, alleging securities fraud and misrepresentation of product performance, have significantly impacted the company's stock price, which has seen sharp declines following financial results disclosures. This event highlights the importance of transparent reporting in the pharmaceutical industry, especially concerning product safety and competitive market dynamics, and could lead to substantial financial penalties for Zoetis and potential recoveries for affected investors.

Pharmaceuticals Legal Services
Event Summary

Multiple investor-rights law firms, including Bronstein, Gewirtz & Grossman, LLC, Rosen Law Firm, Robbins Geller Rudman & Dowd LLP, The Law Offices of Frank R. Cruz, Law Offices of Howard G. Smith, Levi & Korsinsky, Glancy Prongay & Murray, and Bernstein Liebhard LLP, have filed class action lawsuits against Zoetis Inc. The lawsuits allege that Zoetis and its officers made materially false and misleading statements between January 14, 2025, and May 6, 2026, regarding the growth, competitive positioning, market share, and veterinarian adoption of key products within its Companion Animal segment. Specifically, the complaints claim that Zoetis failed to disclose weakening prescription growth for Bedinvetmab due to United States — Food and Drug Administration safety warnings, significant market share loss for Sarolaner to lower-priced competitors, and substantial market share loss for its dermatology products Oclacitinib and Lokivetmab to newly launched treatments. These alleged misrepresentations led to artificially inflated stock prices, and investors suffered significant losses when the truth was revealed through several quarterly financial reports, which showed weakening demand, increased competition, and reduced guidance. Investors have until July 27, 2026, to seek appointment as lead plaintiff in these lawsuits.

Key Actions
100 Robbins Geller Rudman & Dowd LLP filed class action lawsuit Zoetis
100 Bernstein Liebhard LLP filed lawsuit Zoetis
97 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit Zoetis
94 Zoetis reported financial results
92 Rosen Law Firm filed class action lawsuit Zoetis
91 Zoetis made false statements
90 The Law Offices of Frank R. Cruz filed class action lawsuit Zoetis
90 Glancy Prongay & Murray commenced investigation Zoetis
90 Levi & Korsinsky filed class action Zoetis
85 Zoetis released financial results
80 Zoetis released financial results
70 United States — Food and Drug Administration issued safety warnings Bedinvetmab
67 United States — Food and Drug Administration issued safety warnings Zoetis
Entities Involved
stock
Zoetis
Zoetis is the defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about its product performance and market share. The company's stock price has fallen significantly following disclosures of weakening demand and increased competition for its key companion animal products.
Importance 100 Sentiment -75
priv
Robbins Geller Rudman & Dowd LLP
Robbins Geller Rudman & Dowd LLP announces that purchasers of Zoetis securities have until July 27, 2026, to seek appointment as lead plaintiff in the class action lawsuit.
Importance 95 Sentiment 50
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is an investor-rights law firm that has filed a class action lawsuit against Zoetis on behalf of investors who purchased its securities during the Class Period.
Importance 90 Sentiment 50
priv
Rosen Law Firm
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Zoetis securities of the lead plaintiff deadline in the securities class action.
Importance 85 Sentiment 50
priv
The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz continues its investigation of Zoetis Inc. concerning possible violations of federal securities laws.
Importance 80 Sentiment 50
priv
Levi & Korsinsky
Levi & Korsinsky notifies investors in Zoetis Inc. that a class action lawsuit has been filed on behalf of shareholders.
Importance 80 Sentiment 50
priv
Glancy Prongay & Murray
Glancy Prongay & Murray, a leading national shareholder rights law firm, announces a securities fraud class action lawsuit has been filed against Zoetis Inc.
Importance 80 Sentiment 50
priv
Bernstein Liebhard LLP
Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors who purchased Zoetis securities.
Importance 80 Sentiment 50
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued safety warnings concerning serious neurological complications in dogs treated with Bedinvetmab, which contributed to weakening prescription growth for Zoetis' product.
Importance 60 Sentiment 0
per
Kristin Peck
Kristin Peck, CEO of Zoetis, acknowledged a more challenging operating environment and increased price sensitivity among pet owners, leading to a decline in veterinary visits and softer demand.
Importance 60 Sentiment -40
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm, providing contact information for investors interested in joining the class action lawsuit against Zoetis.
Importance 60 Sentiment 40
per
Lawrence Rosen
Lawrence Rosen is a founding partner of Rosen Law Firm, recognized for his work in securities class actions, and is involved in the firm's efforts regarding the Zoetis lawsuit.
Importance 60 Sentiment 40
oth
Bedinvetmab
Bedinvetmab, a canine pain treatment by Zoetis, is cited in the lawsuit for weakening prescription growth due to FDA safety warnings, contributing to the allegations against Zoetis.
Importance 50 Sentiment -40
oth
Sarolaner
Sarolaner, a canine parasiticide by Zoetis, is mentioned in the lawsuit for losing significant market share to competitors, impacting Zoetis's financial performance.
Importance 50 Sentiment -30
oth
Oclacitinib
Oclacitinib, a dermatology product by Zoetis, is losing substantial market share to a newly launched competing treatment, as alleged in the class action lawsuit.
Importance 50 Sentiment -30
+ 14 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.